|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
Human T cell immunity against tumour antigens
If you have a question about this talk, please contact Prof. Jim Kaufman.
Host: Peter Goon (email@example.com)
My group studies human T cells and their potential role in therapy of pre-malignant and malignant diseases. Our main focus has been on human papillomaviruses (HPV) that are associated with the development of cervical cancer. We developed techniques to study HPV specific T cells responses for a series of phase I/II trials with a candidate therapeutic vaccine (TA-HPV). We demonstrated that systemic T cell responses against HPV were relatively weak, both in vaccinated and non-vaccinated patients. Nevertheless we could isolate and grow T cell clones from rare populations, that could kill cancer cells in vitro. This suggests a therapeutic potential for HPV specific T cells but new approaches will be required to induce large numbers of efficacious T cells. We are currently defining new T cell targets based on proteins that are abnormally expressed in cancer. These targets may be applicable to a broad range of human cancers, particularly those caused by oncogenic viruses.
This talk is part of the Immunology in Pathology series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsWorkshop in Microeconomics Danby Society Winton Journal Club
Other talksSeminar by Prof Jinsong Leng, Shape Memory Polymers and Multifunctional Composites, Wednesday 30 July 2014, 16:00-17:00 Goldsmiths 1 Lecture Theatre, Materials Science and Metallurgy Building The 2014 Innate Immunity Summit Regenerative medicine solutions for orthopaedic problems Southern Namibia Planar and outer membrane polarity in the Arabidopsis root epidermis CGHR Research Group